Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Large streamlined trials in cardiovascular disease.

Calvo G, McMurray JJ, Granger CB, Alonso-García Á, Armstrong P, Flather M, Gómez-Outes A, Pocock S, Stockbridge N, Svensson A, Van de Werf F.

Eur Heart J. 2014 Mar;35(9):544-8. doi: 10.1093/eurheartj/eht535. Epub 2014 Jan 2. No abstract available.

PMID:
24385376
2.
3.

Efficient use of endpoints in clinical trials: a clinical perspective.

Terrin ML.

Stat Med. 1990 Jan-Feb;9(1-2):155-60.

PMID:
2111931
4.

Cost and efficiency in clinical trials: the U.S. Physicians' Health Study.

Buring JE, Hennekens CH.

Stat Med. 1990 Jan-Feb;9(1-2):29-33.

PMID:
2345836
5.

Randomized controlled trial and economic evaluation.

Jain S, Arora NK.

Indian J Pediatr. 2000 May;67(5):363-8.

PMID:
10885210
6.
7.

Discussion of papers on cost and efficiency of data collection in clinical trials.

Ellenberg SS.

Stat Med. 1990 Jan-Feb;9(1-2):145-8; discussion 148-51. No abstract available.

PMID:
2345831
8.

Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials.

Coyle D, Davies L, Drummond MF.

Int J Technol Assess Health Care. 1998 Winter;14(1):135-44.

PMID:
9509801
9.

The applicability of results of streamlined trials to clinical practice: the Myocarditis Treatment Trial.

O'Connell JB, Mason JW.

Stat Med. 1990 Jan-Feb;9(1-2):193-6; discussion 196-7.

PMID:
2345835
10.

Explaining community-level variance in group randomized trials.

Feng Z, Diehr P, Yasui Y, Evans B, Beresford S, Koepsell TD.

Stat Med. 1999 Mar 15;18(5):539-56.

PMID:
10209810
11.

Large simple trials: really, it can't be that simple!

Califf RM.

Eur Heart J. 2014 Mar;35(9):549-51. doi: 10.1093/eurheartj/eht556. Epub 2014 Jan 9. No abstract available.

12.

The imperative of overcoming barriers to the conduct of large, simple trials.

Eapen ZJ, Lauer MS, Temple RJ.

JAMA. 2014 Apr 9;311(14):1397-8. doi: 10.1001/jama.2014.1030. No abstract available.

PMID:
24715072
13.

A health-economic evaluation of aspirin: primary prevention and cardiovascular disease.

Sakai T, Saku K.

Intern Med. 2007;46(8):431-3. Epub 2007 Apr 17. No abstract available.

14.

Use of unequal randomisation to aid the economic efficiency of clinical trials.

Torgerson DJ, Campbell MK.

BMJ. 2000 Sep 23;321(7263):759. No abstract available.

15.

Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program.

Hynes D, Reda D, Giobbie-Hurder A, Abdellatif M, Weinberger M, Oddone E, Wasson J, Henderson W.

Med Care. 1999 Apr;37(4 Suppl Va):AS27-36.

PMID:
10217382
16.

ACE inhibitors: back to prime time?

Gupta M, Verma S, Mancini GB.

Heart. 2007 Sep;93(9):1015-6. No abstract available.

17.

Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials.

Takagi H, Umemoto T.

Int J Cardiol. 2012 May 31;157(2):255-7. doi: 10.1016/j.ijcard.2012.01.092. Epub 2012 Feb 21. No abstract available.

PMID:
22360949
18.

Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.

Nelson CL, Sun JL, Tsiatis AA, Mark DB.

Stat Med. 2008 Nov 20;27(26):5525-55. doi: 10.1002/sim.3355.

PMID:
18613251
19.

Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.

Hirst NG, Whitty JA, Synnott RL, Eley DS, Scuffham PA.

J Med Econ. 2011;14(6):698-704. doi: 10.3111/13696998.2011.614304. Epub 2011 Sep 5.

PMID:
21892854
20.

Corporate influence over planning and presentation of clinical trials: beauty and the beast.

Fuchs FD.

Expert Rev Cardiovasc Ther. 2010 Jan;8(1):7-9. doi: 10.1586/erc.09.160. No abstract available.

PMID:
20014930

Supplemental Content

Support Center